Skip to main navigation Skip to search Skip to main content

Use of cytochrome P450-specific parameters and human biomarker data to develop a human physiologically based pharmacokinetic/pharmacodynamic model for dermal chlorpyrifos exposure

  • SUNY Buffalo
  • Ontario Tech University

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

1 Scopus citations

Abstract

Chlorpyrifos (CPF), a widely used organophosphorus pesticide, is metabolized by cytochrome P450s (CYPs) to either an inactive metabolite, trichloro-2-pyridinol (TCPy), or to chlorpyrifos oxon (CPF-oxon), which is a potent Cholinesterase inhibitor. Urinary TCPy levels are a reliable biomarker for CPF exposure while blood Cholinesterase activity is an indicator of CPF toxicity. Previous work with Egyptian agricultural workers involved in CPF application to cotton fields measured urinary TCPy (daily) and blood butyrylcholinesterase and acetylcholinesterase activities (every 7-8 days) as biomarkers of CPF exposure and effect. The urinary TCPy levels and Cholinesterase inhibition values reported for this group of workers exceeds previous published reports of occupational exposure to CPF. A human physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for dermal CPF exposure was developed using the available human biomarker data, CYP-specific kinetic rate constants and other CPF-specific parameters. Human PBPK/PD modeling simulations for a dermal CPF exposure were able to accurately simulate the human exposure and effect biomarker data.

Original languageEnglish
Title of host publicationParameters for Pesticide QSAR and PBPK/PD Models for Human Risk Assessment
PublisherAmerican Chemical Society
Pages309-322
Number of pages14
ISBN (Print)9780841226456
DOIs
StatePublished - 2012

Publication series

NameACS Symposium Series
Volume1099
ISSN (Print)0097-6156
ISSN (Electronic)1947-5918

Fingerprint

Dive into the research topics of 'Use of cytochrome P450-specific parameters and human biomarker data to develop a human physiologically based pharmacokinetic/pharmacodynamic model for dermal chlorpyrifos exposure'. Together they form a unique fingerprint.

Cite this